Oregon Health Authority Health Evidence Review Commission Written Public Comments Feb 2026
Insulet Omnipod Discussed for OHP Diabetes Coverage
Trusted by teams at
Description
Public comments submitted to the Oregon Health Evidence Review Commission describe the Omnipod Insulin Delivery Systems manufactured by Insulet Corporation and urge coverage and adoption by the Oregon Health Plan and Medicaid. Stakeholders highlight clinical benefits and advocate for the inclusion of tubeless/patch/disposable pumps as an option for Type 1 Diabetes patients.
Contract Details
Vendor
INSULET CORPORATION
Agency
Oregon HA | Health Evidence Review Commission, OR
Contract Type
EQUIPMENT
Document Date
February 5, 2026
More from INSULET CORPORATION
Related Contracts
Health Evidence Review Commission and Value-based Benefits Subcommittee Meeting Agenda March 19, 2026
DISCUSSEDHealth Evidence Review Commission and Value-based Benefits Subcommittee Meeting Agenda March 19, 2026
DISCUSSSEDOregon Health Authority Health Evidence Review Commission Written Public Comments Feb 2026
DISCUSSSEDMore from Oregon HA | Health Evidence Review Commission
Oregon HA Health Evidence Review Commission Report Acellular Scaffold Implant March 2026
Oregon Health Authority Public Comments March 2026
Health Evidence Review Commission and Value-based Benefits Subcommittee Meeting Agenda March 19, 2026
Health Evidence Review Commission and Value-based Benefits Subcommittee Meeting Agenda March 19, 2026
Health Evidence Review Commission and Value-based Benefits Subcommittee Meeting Agenda March 19, 2026
Want to learn more?
Get alerts on contract renewals, new awards, and vendor activity.
Bring us your territory.
We'll show you what is forming.
See live SLED buying signals, source docs, decision-makers, contract context, and the next step into your CRM or pipeline.